Globus Medical Reports Strong Q4 and FY 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: NASDAQ.COM
Globus Medical's stock rose by 4.15% as it reached a 20-day high, reflecting positive investor sentiment following its impressive financial results.
In its Q4 2025 report, Globus Medical announced worldwide net sales of $826.4 million, a 25.7% increase from the previous year, and a significant rise in GAAP net income to $140.6 million. The company also projected FY 2026 revenue between $3.18 billion and $3.22 billion, indicating strong future growth potential. This strong performance has solidified investor confidence and contributed to the stock's upward movement.
The robust financial results and optimistic outlook suggest that Globus Medical is well-positioned for continued growth in the musculoskeletal technology sector, attracting investor interest and potentially leading to further stock appreciation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMED
Wall Street analysts forecast GMED stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 80.500
Low
87.00
Averages
101.00
High
114.00
Current: 80.500
Low
87.00
Averages
101.00
High
114.00
About GMED
Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. It separates its products and services into two major categories: Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina Positioned for Strong Growth Ahead
- Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has sharpened its strategy on the core sequencing business, aiming for high-single-digit revenue growth and double-digit to teens EPS growth by 2027, demonstrating a commitment to sustainable growth.
- NovaSeq X Deployments: In Q1 2026, Illumina placed over 80 NovaSeq X units, exceeding expectations and reflecting strong clinical demand, with plans to maintain an average deployment of 50 to 60 units quarterly, further solidifying its market position.
- Clinical Demand Driving Growth: Clinical sequencing consumables demand grew 20% year-over-year in Q1 2026, indicating broader adoption of NGS testing, with expectations that most clinical volumes will transition to the NovaSeq X platform by the end of 2026.
- Challenges in China Market: Despite strong overall performance, Illumina's revenues in Greater China fell 27.8% year-over-year, facing regulatory and geopolitical uncertainties that limit growth potential in the region and may impact overall performance.
See More
Bruker Corporation Shares Surge 50.3% Amid Strong Growth
- Outstanding Stock Performance: Bruker Corporation's shares have surged 50.3% over the past year, significantly outperforming the industry growth of 42.5%, reflecting the company's strong performance in life sciences and materials research, which boosts investor confidence.
- Growth Drivers: The BSI NANO segment reported organic bookings growth exceeding expectations, driving performance in Q1 2026, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating robust market demand.
- Financial Health: As of Q1 2026, the company reported cash and cash equivalents of $133.4 million, down from $298.8 million at the end of 2025, but reduced long-term debt by $181.3 million, lowering net leverage to 2.9X, demonstrating financial stability.
- Competitive Challenges: While the company has gained market share in the preclinical imaging space, it faces pressure from larger competitors, particularly in a softer demand environment for academic and industrial customers, which may impact future growth potential.
See More
Resmed's Acquisition Fuels Growth in Residential Care Software Segment
- Acquisition-Driven Growth: Resmed's strategic acquisitions, including MEDIFOX DAN, have successfully expanded its Residential Care Software segment, which is expected to continue supporting growth in the coming quarters and enhance synergies within its Sleep and Breathing Health franchise.
- Mask Innovation and Resupply: In Q3 of fiscal 2026, Resmed's mask and other sales increased by 14%, driven by new product designs and resupply strategies, which not only improved patient comfort but also supported customer retention in long-term therapy.
- Enhanced Financial Flexibility: As of Q3 fiscal 2026, Resmed reported $1.66 billion in cash, with short-term debt at $260 million and long-term debt at $404 million, resulting in a debt-to-capital ratio improvement to 5.9%, indicating relatively low financial risk.
- Macroeconomic Challenges: Despite Resmed's solid financial performance, it faces challenges from macroeconomic pressures and intense competition, which could impact demand and operating costs, potentially leading to negative effects on the company's overall performance.
See More
Mid-Cap Stock Investment Opportunities Analysis
- DocuSign's Weak Performance: DocuSign (DOCU), with a market cap of $9.9 billion, has shown disappointing average ARR growth of only 8.8% over the past year, indicating challenges in securing long-term deals and renewals, which complicates justifying sales and marketing investments that could enhance revenue growth potential.
- Globus Medical's Strong Growth: Globus Medical (GMED), valued at $10.86 billion, has achieved an impressive annual revenue growth of 30.3% over the past five years, demonstrating resilience in various global economic conditions, while its earnings per share have increased by 22.2% annually, showcasing its strong competitive position in the spine and neurosurgery markets.
- RB Global's Outstanding Market Performance: RB Global (RBA), with a market cap of $19.66 billion, has recorded an annual revenue growth of 26.9% over the past five years, with an adjusted operating margin expansion of 2.5 percentage points, reflecting its scaling efficiency, and its earnings per share have grown by 19.1% annually, significantly outpacing its peers.
- Mid-Cap Investment Outlook: Despite facing competition from larger firms, mid-cap stocks present unique investment opportunities, and StockStory aids investors in identifying companies with solid fundamentals, enabling them to capitalize on market opportunities, particularly in the current economic landscape.
See More
Purcell & Lefkowitz Investigates Globus Medical for Shareholder Rights
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Globus Medical (NYSE:GMED) to determine if the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder interests.
- Shareholder Rights Focus: The investigation aims to protect the rights of Globus Medical shareholders, with the law firm offering free consultations to help shareholders understand their rights and options, thereby enhancing confidence in corporate governance.
- Commitment to Legal Services: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and other corporate misconduct, demonstrating its professionalism and commitment to safeguarding shareholder rights.
- Contact Information Provided: Shareholders seeking more information can directly contact the law firm via email or phone to ensure timely legal support, reflecting the firm's emphasis on client service.
See More
Jim Cramer Expresses Negative Views on Multiple Companies
- Purecycle Technologies Struggles: Jim Cramer highlights that Purecycle Technologies has almost no revenue and is losing a fortune, suggesting investors should avoid this stock, indicating its unfavorable market perception.
- High Risk for Energy Vault Holdings: Cramer describes Energy Vault Holdings as a pure speculative stock that is also losing a fortune, implying its investment value is extremely low and investors should exercise caution.
- Everspin Technologies Overvalued: While Everspin Technologies is profitable, Cramer warns that its price-to-earnings ratio is at 90 times, advising investors to be careful, suggesting that market expectations for its future growth may be overly optimistic.
- Challenges for Rocket Companies: Cramer expresses a negative view on Rocket Companies, stating that even if Kevin Warsh might cut rates, the rising oil prices causing inflation make such cuts unlikely, indicating significant pressure on the company's future prospects.
See More
Illumina Positioned for Strong Growth Ahead
- Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has sharpened its strategy on the core sequencing business, aiming for high-single-digit revenue growth and double-digit to teens EPS growth by 2027, demonstrating a commitment to sustainable growth.
- NovaSeq X Deployments: In Q1 2026, Illumina placed over 80 NovaSeq X units, exceeding expectations and reflecting strong clinical demand, with plans to maintain an average deployment of 50 to 60 units quarterly, further solidifying its market position.
- Clinical Demand Driving Growth: Clinical sequencing consumables demand grew 20% year-over-year in Q1 2026, indicating broader adoption of NGS testing, with expectations that most clinical volumes will transition to the NovaSeq X platform by the end of 2026.
- Challenges in China Market: Despite strong overall performance, Illumina's revenues in Greater China fell 27.8% year-over-year, facing regulatory and geopolitical uncertainties that limit growth potential in the region and may impact overall performance.
See More
Bruker Corporation Shares Surge 50.3% Amid Strong Growth
- Outstanding Stock Performance: Bruker Corporation's shares have surged 50.3% over the past year, significantly outperforming the industry growth of 42.5%, reflecting the company's strong performance in life sciences and materials research, which boosts investor confidence.
- Growth Drivers: The BSI NANO segment reported organic bookings growth exceeding expectations, driving performance in Q1 2026, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating robust market demand.
- Financial Health: As of Q1 2026, the company reported cash and cash equivalents of $133.4 million, down from $298.8 million at the end of 2025, but reduced long-term debt by $181.3 million, lowering net leverage to 2.9X, demonstrating financial stability.
- Competitive Challenges: While the company has gained market share in the preclinical imaging space, it faces pressure from larger competitors, particularly in a softer demand environment for academic and industrial customers, which may impact future growth potential.
See More
Resmed's Acquisition Fuels Growth in Residential Care Software Segment
- Acquisition-Driven Growth: Resmed's strategic acquisitions, including MEDIFOX DAN, have successfully expanded its Residential Care Software segment, which is expected to continue supporting growth in the coming quarters and enhance synergies within its Sleep and Breathing Health franchise.
- Mask Innovation and Resupply: In Q3 of fiscal 2026, Resmed's mask and other sales increased by 14%, driven by new product designs and resupply strategies, which not only improved patient comfort but also supported customer retention in long-term therapy.
- Enhanced Financial Flexibility: As of Q3 fiscal 2026, Resmed reported $1.66 billion in cash, with short-term debt at $260 million and long-term debt at $404 million, resulting in a debt-to-capital ratio improvement to 5.9%, indicating relatively low financial risk.
- Macroeconomic Challenges: Despite Resmed's solid financial performance, it faces challenges from macroeconomic pressures and intense competition, which could impact demand and operating costs, potentially leading to negative effects on the company's overall performance.
See More
Mid-Cap Stock Investment Opportunities Analysis
- DocuSign's Weak Performance: DocuSign (DOCU), with a market cap of $9.9 billion, has shown disappointing average ARR growth of only 8.8% over the past year, indicating challenges in securing long-term deals and renewals, which complicates justifying sales and marketing investments that could enhance revenue growth potential.
- Globus Medical's Strong Growth: Globus Medical (GMED), valued at $10.86 billion, has achieved an impressive annual revenue growth of 30.3% over the past five years, demonstrating resilience in various global economic conditions, while its earnings per share have increased by 22.2% annually, showcasing its strong competitive position in the spine and neurosurgery markets.
- RB Global's Outstanding Market Performance: RB Global (RBA), with a market cap of $19.66 billion, has recorded an annual revenue growth of 26.9% over the past five years, with an adjusted operating margin expansion of 2.5 percentage points, reflecting its scaling efficiency, and its earnings per share have grown by 19.1% annually, significantly outpacing its peers.
- Mid-Cap Investment Outlook: Despite facing competition from larger firms, mid-cap stocks present unique investment opportunities, and StockStory aids investors in identifying companies with solid fundamentals, enabling them to capitalize on market opportunities, particularly in the current economic landscape.
See More
Purcell & Lefkowitz Investigates Globus Medical for Shareholder Rights
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Globus Medical (NYSE:GMED) to determine if the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder interests.
- Shareholder Rights Focus: The investigation aims to protect the rights of Globus Medical shareholders, with the law firm offering free consultations to help shareholders understand their rights and options, thereby enhancing confidence in corporate governance.
- Commitment to Legal Services: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and other corporate misconduct, demonstrating its professionalism and commitment to safeguarding shareholder rights.
- Contact Information Provided: Shareholders seeking more information can directly contact the law firm via email or phone to ensure timely legal support, reflecting the firm's emphasis on client service.
See More
Jim Cramer Expresses Negative Views on Multiple Companies
- Purecycle Technologies Struggles: Jim Cramer highlights that Purecycle Technologies has almost no revenue and is losing a fortune, suggesting investors should avoid this stock, indicating its unfavorable market perception.
- High Risk for Energy Vault Holdings: Cramer describes Energy Vault Holdings as a pure speculative stock that is also losing a fortune, implying its investment value is extremely low and investors should exercise caution.
- Everspin Technologies Overvalued: While Everspin Technologies is profitable, Cramer warns that its price-to-earnings ratio is at 90 times, advising investors to be careful, suggesting that market expectations for its future growth may be overly optimistic.
- Challenges for Rocket Companies: Cramer expresses a negative view on Rocket Companies, stating that even if Kevin Warsh might cut rates, the rising oil prices causing inflation make such cuts unlikely, indicating significant pressure on the company's future prospects.
See More
